Dyskinetic Cerebral Palsy

Dyskinetic cerebral palsy (DCP) is a form of cerebral palsy that can result in a range of developmental delays, physical difficulties, and involuntary muscle movements. DCP is caused by damage to the basal ganglia, a portion of the brain that helps coordinate and control movements.

Valbenazine: An Investigational Therapy for Dyskinetic Cerebral Palsy

Valbenazine, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is thought to work by reducing the amount of dopamine released in a region of the brain that controls movement and motor function.

Clinical Trials: Dyskinetic Cerebral Palsy

Neurocrine Biosciences is currently conducting a Phase 3 study to evaluate the efficacy, safety, and tolerability of valbenazine for the treatment of patients with DCP. For more information about this Phase 3 study, please visit ClinicalTrials.gov.